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nercutaneous coronary intervention (PCI) is frequently
erformed in patients who received fibrinolytic therapy for
cute myocardial infarction (MI). Currently, unfractionated
eparin is the most commonly used antithrombin therapy in
his situation. However, unfractionated heparin has certain
imitations. It has a narrow therapeutic range, monitoring of
he activated clotting time is required, and platelet activa-
ion may be induced. For these reasons, considerable inter-
st has been generated around the question of whether
ow-molecular-weight heparin can be used in place of
nfractionated heparin in the context of high-risk PCI.
ow-molecular-weight heparin provides a more dependable
nticoagulation response than unfractionated heparin, it has
reater antifactor Xa:antifactor IIa activity, and it is less
ikely to induce platelet activation (1). Importantly, how-
ver, cases have been reported of catheter- and guidewire-
ssociated thrombosis during PCI procedures in conjunc-
ion with the use of low-molecular-weight heparin (2,3).
esults from the STEEPLE (Safety and Efficacy of Enox-
parin in Percutaneous Coronary Intervention [PCI] Pa-
ients: an International Randomized Evaluation) trial sug-
est that, when used during elective PCI in low-risk
atients, enoxaparin has similar or lower rates of bleeding
ompared with unfractionated heparin (1). Unfortunately,
he STEEPLE trial was not large enough to provide
efinitive information about ischemic events and procedure-
elated thrombotic events. To date, we have only limited
ata available regarding the safety and efficacy of low-
olecular-weight heparin when used during PCI in high-
isk patients.
See page 2238
In this issue of the Journal, Gibson et al. (4) report the
esults of the PCI substudy from the ExTRACT-TIMI 25
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hysician-Scientist of the Quebec Foundation for Health Research.yocardial Infarction Treatment–Thrombolysis In Myo-
ardial Infarction 25) trial. In that trial (5), over 20,000
atients who received fibrinolytic therapy for ST-segment
levation myocardial infarction (STEMI) were randomized
o unfractionated heparin for at least 48 h versus enoxaparin
or the duration of the index hospitalization. In the substudy
erformed by Gibson et al. (4), data are reported on the
ore than 2,200 patients who underwent PCI in the
noxaparin arm of the trial and the more than 2,400 patients
ho underwent PCI in the unfractionated heparin arm. The
nvestigators found that treatment with enoxaparin was
ssociated with a reduction in death or recurrent MI and no
ifference in major bleeding. They conclude that the use of
noxaparin in the context of PCI after fibrinolytic therapy is
uperior to the use of unfractionated heparin. The authors
re to be congratulated on reporting the results of their
tudy. Until this report, there were very little data available
o guide cardiologists with respect to whether low-
olecular-weight heparin is as safe and efficacious as un-
ractionated heparin during PCI in this high-risk group of
atients. However, several potential limitations of their
tudy should be noted.
First, only a small proportion of the patients who received
brinolytic therapy in the ExTRACT-TIMI 25 trial sub-
equently underwent PCI, and this subgroup of patients was
ot directly randomized to enoxaparin versus unfractionated
eparin. Although the investigators report that the clinical
haracteristics of the PCI patients who received enoxaparin
nd unfractionated heparin were similar, this is not the same
s direct randomization. Using propensity scores can help
ontrol for confounding in this situation, but it cannot
ompletely control for this possibility (6). This problem is
urther compounded by the facts that treatment durations
ere very different among patients receiving enoxaparin and
nfractionated heparin and that, by the time of PCI,
ntithrombin treatment had been unblinded for the major-
ty of the patients.
A second potential limitation is the relative lack of
nformation that is provided about the PCI procedures
hemselves. We are not presented with information such as
umbers of patients who received pretreatment with clopi-
ogrel, the numbers of patients who underwent multivessel
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Editorial Comment June 12, 2007:2247–8CI, the numbers of patients who received stents—both
rug-eluting and bare-metal—and the numbers of patients
ho experienced procedure-related thrombosis. What was
he mean time between the MI and the PCI? What were
he rates of use of rescue PCI? How many patients had
adial procedures? What were the rates of use of closure
evices? The low rate of clopidogrel use suggests that a high
roportion of patients underwent simple balloon angio-
lasty rather than stenting. All of the aforementioned issues
ould potentially impact on the generalizability of the study
esults to practice in North America.
Third, the recently published results from OAT (Oc-
luded Artery Trial) suggest that there is often little benefit
o late PCI in patients who do not reperfuse after STEMI
7). How many of the patients in this substudy fell into that
ategory? Although most patients in North America un-
ergo PCI relatively soon after they receive fibrinolytic
herapy, it appears that many of the patients in the PCI
ubstudy of ExTRACT-TIMI 25 may have been OAT-
ype patients, patients in whom there is now little evidence
f a benefit from PCI.
Finally, there have been several alarming reports of
atheter- and guidewire-associated thrombosis in the set-
ing of PCI when low-molecular-weight heparin is used
2,3). Because of these reports, many clinicians still feel
ncomfortable performing PCI in high-risk patients with
ow-molecular-weight heparin. Although the study by Gib-
on et al. is reassuring in this regard, many clinicians will
ant more definitive data before making the switch.
Thus, although the results reported by Gibson et al. (4)
re virtually the only data available in this subgroup of
atients, I do not believe that it gives us a definitive answer
s to whether enoxaparin can be safely substituted for
nfractionated heparin during high-risk PCI. To provide
he needed data, a clinical trial in which high-risk patients
ndergoing PCI are directly randomized, in a blinded
anner, to the 2 treatment arms, and in which the 2
reatment arms are of similar duration, is required.
Despite the potential limitations noted above, I think that
he study by Gibson et al. (4) makes an important contri-
ution to the literature. The results suggest that low-
olecular-weight heparin may ultimately prove to be safe
nd efficacious as an adjunct to PCI after fibrinolytic therapy
or STEMI. These results are important, given that anti-
hrombin therapy after successful fibrinolysis is often se-
ected by physicians who are not involved in the subsequent
nvasive cardiac care of the patient.
Future directions in this area will involve the investiga-ion of other antithrombin therapies. For example, directhrombin inhibitors such as bivalirudin have been shown to
e effective during PCI in low-risk patients, are cheaper
han the combination of low-molecular-weight heparin or
nfractionated heparin with glycoprotein IIb/IIIa inhibitors
8), and may ultimately prove to be effective in high-risk
atients as well.
Regarding the question as to whether we should substi-
ute fractionated for unfractionated heparin during PCI in
igh-risk patients, I think that the problem still awaits a
efinitive solution.
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